Fortress Biotech, Inc. Business Finance Contracts & Agreements

Credit Agreement entered into by and among Fortress Biotech, Inc., the lenders from time to time party thereto, and Oaktree Fund Administration, LLC on July 25, 2024 (Filed With SEC on September 27, 2024)

Form of Warrant issued to certain affiliates of Oaktree Fund Administration, LLC on July 25, 2024 (Filed With SEC on September 27, 2024)

Form of Securities Purchase Agreement, dated September 19, 2024, by and among the Company and the purchasers party thereto (Filed With SEC on September 23, 2024)

Form of PIPE Warrant (Filed With SEC on September 23, 2024)

Amendment to the Fortress Biotech, Inc. 2012 Employee Stock Purchase Plan (Filed With SEC on May 29, 2024)

Form of Securities Purchase Agreement, dated December 29, 2023, by and among the Company and the purchasers party thereto (Filed With SEC on January 3, 2024)

Form of Warrant (Filed With SEC on January 3, 2024)

Form of Securities Purchase Agreement, dated November 10, 2023, by and among the Company and the purchasers party thereto (Filed With SEC on November 14, 2023)

Form of Warrant (Filed With SEC on November 14, 2023)

Amendment to the Fortress Biotech, Inc. 2012 Employee Stock Purchase Plan (Filed With SEC on June 23, 2023)

Form of Amended and Restated Warrant (Filed With SEC on June 16, 2023)

Form of Contingent Subsidiary Security (Filed With SEC on February 9, 2023)

Form of Securities Purchase Agreement, dated February 7, 2023, by and among the Company and the purchasers party thereto (Filed With SEC on February 9, 2023)

Form of Restricted Stock Unit Agreement (David Jin) (Filed With SEC on October 28, 2022)

Asset Purchase Agreement entered into by and between Journey Medical Corporation and Dermira, Inc. dated as of March 31, 2021 (Filed With SEC on August 16, 2021)

Asset Purchase Agreement entered into by and between Sentynl Therapeutics, Inc. and Cyprium Therapeutics, Inc. dated as of February 23, 2021 (Filed With SEC on August 16, 2021)

Credit Agreement entered into by and among Fortress Biotech, Inc., the lenders from time to time party thereto, and Oaktree Fund Administration, LLC on August 27, 2020 (Filed With SEC on August 16, 2021)

Asset Purchase Agreement entered into by and between Journey Medical Corporation and Dermira, Inc. dated as of March 31, 2021 (Filed With SEC on May 17, 2021)

Asset Purchase Agreement entered into by and between Sentynl Therapeutics, Inc. and Cyprium Therapeutics, Inc. dated as of February 23, 2021 (Filed With SEC on May 17, 2021)

Credit Agreement entered into by and among Fortress Biotech, Inc., the lenders from time to time party thereto, and Oaktree Fund Administration, LLC on August 27, 2020 (Filed With SEC on May 17, 2021)

Credit Agreement entered into by and among Fortress Biotech, Inc., the lenders from time to time party thereto, and Oaktree Fund Administration, LLC on August 27, 2020 (Filed With SEC on November 9, 2020)

Underwriting Agreement, dated August 26, 2020, by and among Fortress Biotech, Inc., The Benchmark Company, LLC and ThinkEquity, a division of Fordham Financial Management, Inc (Filed With SEC on August 28, 2020)

Underwriting Agreement, dated May 26, 2020, by and among Fortress Biotech, Inc., The Benchmark Company, LLC and ThinkEquity, a division of Fordham Financial Management, Inc (Filed With SEC on May 28, 2020)

Underwriting Agreement, dated February 11, 2020, between Fortress Biotech, Inc., The Benchmark Company, LLC and ThinkEquity, a division of Fordham Financial Management, as... (Filed With SEC on February 12, 2020)

Underwriting Agreement, dated November 25, 2019, between Fortress Biotech, Inc., The Benchmark Company, LLC and ThinkEquity, a division of Fordham Financial Management, as... (Filed With SEC on November 26, 2019)

Development, Option and Stock Purchase Agreement dated January 30, 2019 by and among Fortress Biotech, Inc., Caelum Biosciences, Inc. (Caelum), Alexion Therapeutics, Inc., and the... (Filed With SEC on May 10, 2019)

Stock Purchase Agreement by and among FBIO Acquisition, Inc., Fortress Biotech, Inc., and NHC Holdings, LLC, dated November 14, 2018 (Filed With SEC on November 20, 2018)

Waiver Agreement, dated as of November 12, 2018, by and between Fortress Biotech, Inc., Avenue Therapeutics, Inc. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 16, 2018)

Guaranty, dated as of November 12, 2018, by and between Fortress Biotech, Inc. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 16, 2018)

Credit Agreement, dated as of November 12, 2018, by and between Avenue Therapeutics, Inc. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 16, 2018)

Amended and Restated Credit Facility Agreement dated as of March 12, 2018, by and among Fortress Biotech, Inc. and Opus Point Healthcare Innovations Fund, L.P (Filed With SEC on March 16, 2018)

Underwriting Agreement, dated November 6, 2017, between Fortress Biotech, Inc. and B. Riley FBR, Inc., as representative of the several underwriters named therein (Filed With SEC on November 7, 2017)

FORM OF FORTRESS BIOTECH,INC. PROMISSORY NOTE (Filed With SEC on May 10, 2017)

FORM OF NOTE PURCHASEAGREEMENT (Filed With SEC on May 10, 2017)

FORM OF COMMON STOCK PURCHASEWARRANT To Purchase [_____] Shares of Common Stockof Fortress Biotech, Inc. (Filed With SEC on May 10, 2017)

PLEDGE AND SECURITY AGREEMENT (Filed With SEC on November 9, 2016)

FORM OFCOMMON STOCK PURCHASE WARRANT To Purchase [___________] Sharesof Common Stock of Fortress Biotech, Inc. (Filed With SEC on November 9, 2016)

Form of Fortress Biotech, Inc. CONVERTIBLE SECUREDPROMISSORY NOTE (Filed With SEC on November 9, 2016)

CREDIT FACILITY AGREEMENT (Filed With SEC on November 9, 2016)

FORTRESS BIOTECH, INC. Common Stock (par value $0.001 per share) Amended and Restated At Market IssuanceSales Agreement (Filed With SEC on August 17, 2016)

Category

Industry

Companies

Contracts

Fortress Biotech, Inc. Business Finance Contracts & Agreements